Panel Discussion: Addressing the Key Challenges for Potency Assay Strategies for TIL Candidates

Time: 1:30 pm
day: Day Two


• Discussing tumor specific vs. tumor-antigen specific assays and ideal tumor target material
• Addressing the need for robust, reliable and reproducible assays for TIL therapies
• TIL is a complex, patient-specific therapy, including product variability against unknown antigen specificity